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BACKGROUND: Around 60% of women X80 years old, in the UK do not have surgery for their breast cancer (vso10% of younger
age groups). The extent to which this difference can be accounted for by co-morbidity has not been established.
METHODS: A Cancer Registry/Hospital Episode Statistics-linked data set identified women aged X65 years diagnosed with invasive
breast cancer (between 1 April 1997 and 31 March 2005) in two regions of the UK (n¼ 23 038). Receipt of surgery by age was
investigated using logistic regression, adjusting for co-morbidity and other patient, tumour and treatment factors.
RESULTS: Overall, 72% of older women received surgery, varying from 86% of 65–69-year olds to 34% of women aged X85 years.
The proportion receiving surgery fell with increasing co-morbidity (Charlson score 0¼ 73%, score 1¼ 66%, score 2þ ¼ 49%).
However, after adjustment for co-morbidity, older age still predicts lack of surgery. Compared with 65–69-year olds, the odds of
surgery decreased from 0.74 (95% CI: 0.66–0.83) for 70–74-year olds to 0.13 (95% CI: 0.11–0.14) for women aged X85 years.
CONCLUSION: Although co-morbidity is associated with a reduced likelihood of surgery, it does not explain the shortfall in surgery
amongst older women in the UK. Routine data on co-morbidity enables fairer comparison of treatment across population groups but
needs to be more complete.
British Journal of Cancer (2012) 107, 1175–1180. doi:10.1038/bjc.2012.192 www.bjcancer.com
Published online 9 August 2012
& 2012 Cancer Research UK
Keywords: co-morbidity; breast cancer; older; surgery





















































Older women experience the highest incidence and worst survival
for breast cancer in England (Cancer Research UK, 2009; Office for
National Statistics, 2010). The relative 5-year survival for women
diagnosed with breast cancer in England between 2001 and 2006
falls from 90% for 50–59-year olds to 69% for women aged X80
years old; a drop in survival of a scale not seen in comparable
countries (Cancer Research UK, 2009; Coleman et al, 2011).
Similar patterns by age have also been seen for cause-specific
survival in the UK (Ali et al, 2011). It has been suggested that
improved management of older cancer patients has a key role in
improving overall cancer survival in England, and for age-based
access to treatment to be investigated as a priority (Foot and
Harrison, 2011).
Studies from the UK, North America and Europe demonstrate
substantial differences in the management of older women with
breast cancer (Bouchardy et al, 2007; Louwman et al, 2007;
Lawrence et al, 2011). Care of older women is less likely to be in
accordance with treatment guidelines. They are less likely to
receive primary surgery, radiotherapy following breast conserving
surgery or chemotherapy (Wyld et al, 2004; Giordano et al, 2005;
Naeim et al, 2006; Lavelle et al, 2007b). Lack of surgical
management appears to be a particular problem for older breast
cancer patients in the UK, only 39% of women aged X80 years
presenting with symptomatic breast cancer in 2007 had surgery
compared with 90% of those aged under 50 years (Lawrence et al,
2011). Similar patterns have been demonstrated in previous UK
studies (Wyld et al, 2004; Lavelle et al, 2007a, b).
Treatment guidelines for early-stage breast cancer are largely
based on trials, which under-represented older women (Scottish
Intercollegiate Guidelines Network, 2005; Association of Breast
Surgery at BASO, 2009; National Institute for Clinical Excellence,
2009) and there has been debate about the extent to which their
results can be applied to older patients (Balducci et al, 2001; Ring
et al, 2011). However, the current policy on treatment of cancer
for the elderly in the UK is given in the Cancer Reform Strategy
(CRS) (Department of Health, 2007). While acknowledging the
importance of ongoing trials, it states that patient health and
patient choice are the only acceptable reasons for older breast
cancer patients not receiving clinically appropriate treatment. This
approach is supported in management of breast cancer by a
systematic review comparing surgery plus endocrine therapy with
endocrine alone in women aged X70 years, which reported
poorer progression-free survival without surgery. The authors
concluded surgery should only be omitted in women with
oestrogen receptor-positive tumours who are ‘unfit for, or refuse,
surgery’ (Hind et al, 2007).
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One measure of patient health/fitness is co-morbidity (i.e.,
pre-existing illness in addition to the primary diagnosis).
Co-morbidity can be measured in several ways, including scoring
individual patients’ health records or using information extracted
from administrative databases, for example, the Charlson Index
(Charlson et al, 1987), or Index of Co-existing Diseases (Imamura
et al, 1997). The value of routine adjustment for co-morbidity
applicable to large data sets has been emphasised in facilitating
fairer interpretation of practice across the patient groups (National
Cancer Intelligence Network, 2010).
Despite the recognised importance of adjustment for co-morbidity,
previous UK studies which do this, for older breast cancer patients,
are limited to a small prospective cohort study (n¼ 76), which scored
co-morbidity directly from case notes of women agedX65 years with
early-stage breast cancer. The authors found the odds of women aged
X80 years not having surgery for operable (stage I-IIIa) disease were
44 times that of women aged 65–79 years, even when adjusted for co-
morbidity (Lavelle et al, 2007a).
Larger-scale studies have been undertaken in the United States,
using diagnostic data held on administrative databases. All
demonstrate that older age continues to predict not having
surgery even when co-morbidity is adjusted for (Hillner et al,
1996; Giordano et al, 2005). The generalisability of these results to
the UK, is limited by differences between the health care systems
and survival rates (Coleman et al, 2008).
Recent developments in data linkage in England between cancer
registration and hospital in-patient admission data (the Hospital
Episode Statistics, HES) (Health and Social Care Information
Centre, 2009) provides a new opportunity to develop and adjust
for routine measure of co-morbidity. This study focuses on the
treatment of breast cancer in women, aged X65 years, using
cancer registry data linked to HES to investigate disparities in
primary surgery by age and whether adjustment for co-morbidity,
can explain any differences found.
METHODS
Analyses were based on a data set of all registrations with invasive
breast cancer (ICD C50) in females agedX65 years in two English
cancer registries serving the Northern and Yorkshire (region 1,
catchment population 6.6M) and West Midlands (region 2,
catchment 5.3M) between 01 April 1997 and 31 March 2005
(n¼ 29 336). These were matched to an extract of HES available to
English cancer registries, which include records of all individuals
with at least one instance of a recorded diagnosis of cancer.
Matching was based on all or combinations of: unique NHS
number, date of birth and postcode at diagnosis. Patients treated
in hospitals outside the two regions, or in private hospitals, were
excluded. This resulted in a data set of 23 038 women (79% of all
registrations in this age range) in which co-morbidity could be
assessed. Surgical treatment was identified from standard proce-
dure codes for mastectomy (OPCS B271-275, B278-279) and
breast-conserving surgery (BCS) (B281-283, B288-289). Women
were classified as receiving primary surgery if they had
mastectomy or BCS recorded within 6 months of diagnosis
or had these treatments recorded but the date of treatment was
not known, or had a record of having received these treatments in
the cancer registration data.
A Charlson co-morbidity score was calculated for each
individual based on the diagnostic codes (excluding cancer)
recorded from Hospital Episode Statistic in hospital admissions
in the year before diagnosis (Charlson et al, 1987). The cancer
component (i.e., pre-existing cancer) of the score was drawn from
cancer registry data. For this study population, the Charlson scores
ranged from 0 (no co-morbidities) to 7 (severe co-morbidity)
and were grouped for analysis.
Patient age, stage of disease (using a modified version of the
TNM system (UICC, 2002) with stage categorised as I, II, III, IV or
missing), tumour grade (well, moderate, poorly differentiated or
missing) (Bloom and Richardson, 1957), period of diagnosis
(1997–99, 2000–02 or 2003–05) and region were obtained from the
cancer registry data. An area-based measure of socioeconomic
background, the 2004 Index of Multiple Deprivation Income
Domain (Office of the Deputy Prime Minister, 2005) was derived
from the postcode at diagnosis. Self-reported ethnicity was derived
from HES data (categorised as White, non-White).
All explanatory variables were investigated in univariable
analysis using Pearson’s w2 test, w2 test for trend and univariable
logistic regression analyses to generate odds ratios (ORs) (two-
tailed with a¼ 0.05). Those that were significantly associated with
the outcome (primary surgery) were included in an initial
multivariable regression analysis from which variables where
excluded on the following basis; (1) no significant effect or (2)
significant effect only in the ‘missing’ category of data. The
covariates included in the final model were age (as a categorical
variable), co-morbidity score (0, 1, 2þ ), stage, region and period
of diagnosis. The results are presented as ORs with 95% confidence
intervals (CIs). Sensitivity analyses were conducted on data sets
restricted to individuals with early-stage disease (I and II), and
excluding the most elderly patients (X85 years).
The development of the data set used in this study was approved
by the Department of Health Patient Information and Advisory
Group (PIAG 2-05(f)/2007). Ethical approval was received by the
Department of Health Sciences Research Governance Board
(University of York 11 February 2009).
RESULTS
In total, 23 038 of the 29 336 (79%) cancer registrations for invasive
breast cancer had a matching HES record and hence a potential
measure of co-morbidity. The proportion of registrations with
matching HES records varied with age, with lower levels in the
most elderly (65–69¼ 87%, 70–74¼ 86%, 75–79¼ 82%,
80–84¼ 73%, X85¼ 58%). Reasons for non-linkage include a
missing NHS number, or the patient’s cancer being recorded on
the registry by Death Certification Only (DCO). In the case of a
DCO it would be unlikely for the patient to be included in the HES
data extract, which was conditional on a recorded cancer diagnosis
at some point. The proportion of registrations missing an NHS
number was small (o2%) and did not change significantly with
age. However, the DCO rate did change with a higher level for
those agedX85 years (65–69¼ 0.6%, 70–74¼ 1.0%, 75–79¼ 1.7%,
80–84¼ 2.7%, X85¼ 7.6%).
The overall characteristics of the group are described in Table 1.
Approximately, 50% of the women were aged 65–74 years, 38%
75–84 years, and 12% over 85 years. Nearly two thirds of the
sample (65.4%) were recorded with early-stage disease (I or II) at
diagnosis, 8.6% were stage III and 6.1% presented with metastatic
(stage IV) disease. For 19.9% no stage was recorded. Regarding co-
morbidity, 85.7% had no co-morbid conditions identified in
diagnostic codes of in-patient admissions, 10.0% had a Charlson
score of 1 and 4.3% scored 2 or more. Co-morbidity scores
increased with age with the proportion with Charlson score X1
being 11.5% amongst 65–69-year olds and 19.6% for women aged
85þ (Figure 1). Co-morbidity was also greater in those living in
more deprived areas (score X1: least-deprived quintile¼ 11.2%;
2nd quintile¼ 11.2%; 3rd quintile¼ 14.1%; 4th quintile¼ 15.2%;
most deprived quintile¼ 18.0% P(trend) o0.001) and increased
across time (score X1: 1997–99¼ 11.0%; 2000–02¼ 14.0%;
2003–05¼ 18.7% P(trend) o0.001).
Overall, 71.6% received primary surgery. The proportion of
women receiving surgery decreased substantially with older age
(Table 2). Just over 86% of 65–69-year olds had surgery compared
with around a third of women aged X85 years. Of those with no
recorded co-morbidities, 73.4% underwent surgery, compared with
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66.2% of those with a score of 1 and 49.1% of those with a score of
2þ . Across all age groups a smaller proportion of the patients with
co-morbidity (score of 1þ ) had surgery compared with those with
no co-morbidity (Figure 2). However, the difference in surgical
rates was most pronounced for women aged 70–85 years with a
co-morbidity score of 2þ . Women with metastatic (stage IV) or
unknown stage of breast cancer were much less likely to have
surgery than those with earlier-stage disease. Just under 90% of
women with early-stage breast cancer in the whole sample had
surgery compared to only 16.6% of those with stage IV and 36.5%
Table 1 Characteristics of the study population
Variable Category n Percent
Age group 65–69 5769 25.0
70–74 5650 24.5
75–79 5205 22.6
80–84 3566 15.5
85þ 2848 12.4
Co-morbidity 0 19 749 85.7
1 2310 10.0
2þ 979 4.3
Stage I 6036 26.2
II 9035 39.2
III 1974 8.6
IV 1415 6.1
Missing 4578 19.9
Grade 1 3492 15.2
2 9125 39.6
3 5464 23.7
Missing 4957 21.5
Deprivation 1 (Affluent) 3309 14.4
2 4528 19.7
3 4643 20.1
4 4974 21.6
5 (Deprived) 5556 24.1
Missing 28 0.1
Ethnicity White 19 043 82.7
Non-white 275 1.2
Missing 3720 16.1
Region 1 12 669 55.0
2 10 369 45.0
Diagnosis period 1997–99 7377 32.0
2000–02 8685 37.7
2003–05 6976 30.3
Total 23 038 100
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Figure 1 Chrison co-morbidity scores by age group.
Table 2 Number and proportion of women having primary surgery
Variable Category No. of surgery % Surgery
Age group* 65–69 4983 86.4
70–74 4564 80.8
75–79 3826 73.5
80–84 2161 60.6
85þ 970 34.1
Co-morbidity* 0 14 494 73.4
1 1529 66.2
2þ 481 49.1
Stage* I 5351 88.7
II 7896 87.4
III 1352 68.5
IV 235 16.6
Missing 1670 36.5
Grade* 1 2955 84.6
2 7619 83.5
3 4653 85.2
Missing 1277 25.8
Deprivation* 1 (Affluent) 2492 75.3
2 3422 75.6
3 3302 71.1
4 3510 70.6
5 (Deprived) 3762 67.7
Ethnicityw White 13 826 72.6
Non-white 213 77.5
Missing 2465 66.3
Regionw 1 8910 70.3
2 7594 73.2
Diagnosis period* 1997–09 4970 67.4
2000–02 6298 72.5
2003–05 5236 75.1
Total 16 504 71.6
All variables highly associated with receipt of surgery, that is, *P (trend) o0.001;
wP (Person) o0.001.
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of those with missing stage. There was little difference in the
proportion of women receiving surgery by disease grade 1, 2 or 3
(well, moderately or poorly differentiated; 84.6%, 83.5% and
85.2%, respectively), but only 25.8% of those with missing
information on grade had surgery. Treatment was also socially
patterned. The proportion of women undergoing surgery was
75.3% in the most affluent quintile and this decreased to 67.7% in
the most deprived quintile. There was some suggestion that non-
White women were more likely to have surgery (77.5%) than
White women (72.6%) but the numbers in the non-White category
were very small. Women living in region 1 were slightly less likely
to have surgery than women living in region 2 (70.3% compared to
73.2%). The proportion of women who had surgery increased with
each successive diagnosis period, from 67.4% in 1997–99 to 75.1%
in 2003–05.
The results of univariable and multivariable logistic regression
models are shown in Table 3. In univariable analysis, the odds of
receiving surgery diminished substantially with increasing age,
with women aged X85 years having 0.08 (95% CI: 0.07–0.09) the
odds of surgery compared with women aged 65–69 years.
After controlling for the effect of co-morbidity (as well as other
explanatory variables), age remained strongly predictive of surgery
with the odds of receipt significantly lower for all age groups X70
years compared with 65–69-year olds. Women with any co-
morbidity had significantly lower odds of receiving surgery
compared with those with no co-morbidity (adjusted OR 0.75,
95% CI: 0.67–0.84 for those with a score of 1; adjusted OR 0.40,
95% CI: 0.34–0.48 for those with a score of 2þ ). Women with later
stage and unknown stage breast cancer had reduced odds of
surgery compared with those with stage 1 (adjusted OR 0.34, 95%
CI: 0.30–0.39 for stage III; adjusted OR 0.02, 95% CI: 0.02–0.03 for
stage IV; adjusted OR 0.10, 95% CI: 0.09–0.11 for missing stage).
Region had an effect on receipt of surgery, women treated in
region 2 had 1.70 times the odds of having surgery compared with
women treated in region 1 (95% CI: 1.58–1.84). Surgical rates
increased over time with women diagnosed in the more recent time
periods being more likely to receive surgery (adjusted OR 1.17, 95%
CI: 1.08–1.28 for 2000–02; adjusted OR 1.29, 95% CI: 1.17–1.41 for
2003–05) compared with women diagnosed in 1997–99. Associations
between age, surgery and co-morbidity were unaltered in analyses
restricted to both early-stage disease and women aged under 85 years
(data available online Tables S1 and S2).
DISCUSSION
To our knowledge, this is the first large-scale population-based
study of treatment patterns for older women with breast cancer in
the UK to incorporate a measure of co-morbidity. We confirmed
that increasing age predicted lack of primary surgery for all age
groups X70, compared with 65–69-year olds. This disparity in
treatment by age was evident in the whole sample, across both
constituent regions and persisted when co-morbidity was adjusted
for. This finding is in broad agreement with studies from the North
America (Hillner et al, 1996; Giordano et al, 2005; Naeim et al,
2006) and the UK (Lavelle et al, 2007a).
Co-morbidity explained some of the variation observed in
treatment. Although co-morbidity has been found to predict
under-treatment in several previous studies of older women with
breast cancer (Ballard-Barbash et al, 1996; He´rbert-Croteau et al,
1999; Giordano et al, 2005; Naeim et al, 2006), this is by no means
a universal finding (Hillner et al, 1996; Silliman et al, 1997;
Mandelblatt et al, 2000; Lavelle et al, 2007a). However, even after
accounting for co-morbidity all of these studies still found older
women were less likely to receive some aspect of standard
treatment.
The two registries included in the study are broadly representa-
tive in terms of population structure and level of deprivation;
covering approximately 23% of the population of England and
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Figure 2 The proportion of patients having surgery by age group stratified by Charlson co-morbidity score.
Table 3 Multivariable logistic regression of receiving primary surgery
(vs not receiving primary surgery)
Variablea Category
Unadjusted
odds ratio 95% CI
Adjusted
odds ratiob 95% CI
Age group 65–69 (Ref) — (Ref) —
70–74 0.66 0.60–0.73 0.74 0.66–0.83
75–79 0.44 0.40–0.48 0.56 0.50–0.63
80–84 0.24 0.22–0.27 0.32 0.28–0.36
85þ 0.08 0.07–0.09 0.13 0.11–0.14
Co-morbidity 0 (Ref) — (Ref) —
1 0.71 0.65–0.78 0.75 0.67–0.84
2þ 0.35 0.31–0.40 0.40 0.34–0.48
Stage I (Ref) — (Ref) —
II 0.89 0.80–0.98 1.01 0.91–1.13
III 0.28 0.25–0.32 0.34 0.30–0.39
IV 0.03 0.02–0.03 0.02 0.02–0.03
Missing 0.07 0.07–0.08 0.10 0.09–0.11
Region 1 (Ref) — (Ref) —
2 1.15 1.09–1.22 1.70 1.58–1.84
Diagnosis period 1997–99 (Ref) — (Ref) —
2000–02 1.28 1.19–1.37 1.17 1.08–1.28
2003–05 1.46 1.35–1.57 1.29 1.17–1.41
Abbreviation: CI¼ confidence interval. aDeprivation, not included as no significance
effect in initial multivariable model. Grade and ethnicity not included as effect in initial
multivariable model only in missing categories of data. bAdjusted for all other variables
in the table.
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35 of the 168 Acute NHS Hospital Trusts in the country. They have
high-quality data, meeting all UKACR performance targets on
completeness of breast cancer staging and treatment data (United
Kingdom Association of Cancer Registries, 2011).
The routine measure of co-morbidity used in this study has
informed, and been developed in the light of, national-level
discussions (National Cancer Intelligence Network, 2010).
This study represents an important step forward in building on
these discussions to develop a routine measure of co-morbidity.
The observed Charlson scores followed the anticipated patterns
with patient age and social position. In line with other studies,
estimated co-morbidity scores increased over time, probably due
to increased recording of additional ‘secondary diagnoses’ within
HES in more recent years (Trotter et al, 2008). The measure used
here exhibits a strong association with receipt of surgery and
accounts for some of the variation in surgery by age group.
Although the use of routine data does not confer the same level of
control over data collection as prospective, individual-level
studies, the method used here enabled investigation of treatment
patterns on a large scale from which a routine measure of co-
morbidity could be investigated. This provides a basis for further
work to refine this routine measure and thereby provide the basis
for a more level playing field for population/institutional
comparisons of treatment access and outcomes.
A large sample size was achieved by using administrative data to
score co-morbidity rather than reviewing individual medical
records, but this approach has limitations. Administrative records
drawn from secondary care underestimate cancer patient’s
total co-morbidity as they are based only on in-patient
hospital admissions. Underestimation of co-morbidity is apparent
in the lower proportion of older breast cancer patients having a
Charlson score ofX1 in this study (14%) when compared with the
previous studies measuring co-morbidity from individual
case note reviews (varies from 17–35%) (Ballard-Barbash
et al, 1996; He´rbert-Croteau et al, 1999; Hurria et al, 2003;
Lavelle et al, 2007a).
Measurement of co-morbidity in this study was also dependent
on linkage between data sets and there was evidence that this
decreased with older age; the sample used in this study will under-
represent the oldest patients. The increase in proportion of cases
registered via DCO with older age is likely to have contributed to
the reduction in linkage as the HES data set currently available to
the registries (and hence this study) is restricted to patients with a
recorded diagnosis of cancer at some point. However, among those
under 85 years old, where linkage rates are reasonably high, the
pattern of access to surgery decreasing with older age, accounting
for co-morbidity, is clearly demonstrated. There is evidence that
the degree of linkage achievable in the oldest patients has
improved in recent years, the National Cancer Data Repository
containing merged data from cancer registries and HES shows an
increase in linkage for breast cancer patients aged X85 years old,
from 44.3% in 1997 to 68.7% in 2007 (National Cancer Information
Network, 2010; Northern and Yorkshire Cancer Registry and
Information Service, 2011).
We found some differences between the two regions. National
audit data for the UK suggest considerable variation in standard
management between provider units, with the proportion of breast
cancer patients aged X70 years not receiving surgery varying
between regions from 12 to 40% (Breast Cancer Clinical Outcome
Measures Project, 2007) and between hospitals from 8 to 77%
(Monypenny, 2004). Although the authors acknowledge that it is
possible that this reflects a true difference in clinical practice, they
conclude that this variation is more likely to be due to under-
reporting to cancer registries of cases that were not surgically treated.
Treatment guidelines recommend surgery as the primary
treatment for early-stage breast cancer. However, stage at
diagnosis as recorded in cancer registries has been largely
based on surgical specimens. Restricting the sample to early-stage
breast cancer would have conditioned our analyses on the basis of
the primary outcome, that is, selectively excluding women not
undergoing surgery. However, when analyses were limited to
patients with stage I and II disease identical patterns were seen,
with less surgery observed in older women and only limited
attenuation of this affect when adjusted for co-morbidity.
The results of this study suggest that for women agedX65 years
the chance of surgery increased with time over the 9 years of the
study. Although this may in part reflect improving completeness of
treatment data, increasing surgical rates over time have also been
reported in national audits (National Clinical Audit Support
Programme, 2009). It therefore seems likely that the improved
surgical rates also demonstrate changes in practice, reflecting the
guidelines that were published and the major reorganising of
cancer services over the period of time covered by this study
(1997–2005) (Clinical Oncology Information Network (COIN),
1999; British Association of Surgical Oncologists (BASO), 1998;
Scottish Intercollegiate Guidelines Network, 2005; Department of
Health, 2000).
The Cancer Reform Strategy states that the only acceptable
reasons for cancer patients not receiving clinically appropriate
treatment are poor patient health and choice (Department of
Health, 2007). However, in order to truly measure suboptimal
treatment, the potential confounding effects of these factors need
to be adjusted for. In this study, we adjusted for co-morbidity, but
wider measures of health such as functional health/ performance
status (or frailty) have also been found to predict under-treatment
of older breast cancer patients (Lavelle et al, 2007a) independently
from co-morbidity (Extermann et al, 1998). In our study, the
largest difference in surgical rates by co-morbidity occurs for
women aged 79–84 years, perhaps indicating a greater influence
from wider measures of health for patients aged over 85 years. Two
cohort studies in the USA have attempted to measure and account
for patient choice in clinical decisions for older women with breast
cancer. Although both found that patient’s preferences were
associated with treatment, increasing age remained strongly
predictive of under-treatment in models accounting for patient
choice (Silliman et al, 1997; Mandelblatt et al, 2000). Further
prospective, cohort studies are currently being undertaken in the
UK to investigate the extent to which patients choice and poor
health explains the difference is treatment between older and
younger women in this country (UK Clinical Research Network
Portfolio Database, 2011a, b).
The results of this study indicate that although co-morbidity is
associated with a reduced likelihood of surgery, it does not explain
the shortfall in surgery among older women in the UK. However,
investigation of age-bias in access to treatment requires further
research on two fronts. Routine measures of co-morbidity need
further development to ensure completeness and thereby a means
of fairer comparison of access to surgery between demographic
groups on a national level. In addition, prospective cohort studies
are needed to examine the extent to which co-morbidity and wider
measures of health (such as frailty) as well as patient choice
explain the lack of surgery for older breast cancer patients.
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